Nicolet Advisory Services LLC Buys 430 Shares of GSK plc (NYSE:GSK)

Nicolet Advisory Services LLC raised its stake in GSK plc (NYSE:GSK) by 3.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 13,215 shares of the pharmaceutical company’s stock after acquiring an additional 430 shares during the period. Nicolet Advisory Services LLC’s holdings in GSK were worth $507,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Nwam LLC bought a new stake in GSK during the 3rd quarter valued at about $625,000. Raymond James Trust N.A. increased its position in shares of GSK by 6.9% during the third quarter. Raymond James Trust N.A. now owns 45,948 shares of the pharmaceutical company’s stock valued at $1,878,000 after acquiring an additional 2,969 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in GSK by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,603 shares of the pharmaceutical company’s stock valued at $4,971,000 after acquiring an additional 14,687 shares in the last quarter. Integrated Investment Consultants LLC purchased a new stake in GSK during the 3rd quarter valued at $2,761,000. Finally, Primecap Management Co. CA increased its holdings in shares of GSK by 2.4% in the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock worth $607,222,000 after purchasing an additional 342,365 shares in the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Trading Up 0.8 %

Shares of GSK stock opened at $33.96 on Friday. GSK plc has a 1 year low of $32.83 and a 1 year high of $45.92. The firm has a fifty day moving average price of $38.09 and a 200-day moving average price of $40.35. The company has a market cap of $70.38 billion, a price-to-earnings ratio of 22.05, a PEG ratio of 1.29 and a beta of 0.66. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, January 9th. Stockholders of record on Friday, November 15th will be paid a $0.3928 dividend. The ex-dividend date is Friday, November 15th. This represents a $1.57 annualized dividend and a dividend yield of 4.63%. This is an increase from GSK’s previous quarterly dividend of $0.38. GSK’s dividend payout ratio (DPR) is 99.35%.

Analysts Set New Price Targets

GSK has been the topic of several recent analyst reports. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. Argus upgraded shares of GSK to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, Barclays upgraded GSK to a “hold” rating in a research note on Tuesday, August 27th. Seven investment analysts have rated the stock with a hold rating and three have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.25.

Insider Transactions at GSK

In other news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, for a total transaction of $22,335,440.00. Following the transaction, the insider now directly owns 16,775,691 shares of the company’s stock, valued at approximately $134,205,528. This trade represents a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 10.00% of the company’s stock.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.